arrow
J

Jaroslaw P. Maciejewski

cleveland clinic cancer center
H指数:106
被引数:4.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Emergency hematopoiesis in sepsis: A pathway to myeloid clonal expansion

脓毒症中的应急造血:髓系克隆扩增的途径

2026-10-300
OAAI
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Multilineage lymphoid clonal hematopoiesis: a cross-sectional, correlative analysis of plasma cell dyscrasias and large granular lymphocytic leukemia

多系谱系淋巴细胞克隆性造血:浆细胞异常和大型颗粒淋巴细胞白血病的横断面相关性分析

Leukemia
IF13.4
2026-08-050
OA
Molecular and clinical analyses of c-CBL mutations affecting tyrosine 371 in myelodysplastic and proliferative disorders

c-CBL基因中影响酪氨酸371突变的分子和临床分析在骨髓增生异常和增殖性疾病中的应用

Leukemia
IF13.4
2026-07-220
OAAI
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia

再生障碍性贫血中克隆造血和结构变异的高分辨率单细胞定位

2026-05-010
PRE
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议

2026-04-010
PRE
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

DDX41突变髓系肿瘤挑战现有的预后方案,并需要专门的危险评分系统:一项多中心、回顾性研究

Leukemia
IF13.4
2025-12-030
PRE
Telomere content and genomics of myeloid neoplasia by WGS

端粒含量和髓系肿瘤的全基因组测序(WGS)基因组学

Blood
IF23.1
2025-09-240
OA
C-CBL MUTATIONS AFFECTING RESIDUE 371 ARE INDEPENDENTLY CORRELATED WITH DISMAL PROGNOSIS IN MDS AND CMML GUIDED POSTER VIEWING SESSION 1: THERAPY-PART I

影响371位残基的C-CBL突变在MDS和CMML中与不良预后独立相关 指导的海报观看会1:治疗-第一部分

2025-09-010
PRE
TELOMERE CONTENT IN MYELOID NEOPLASIA COULD INFORM ON DIFFERENTIAL SENSITIVITY TO TELOMERASE INHIBITORS

髓系肿瘤中的端粒含量可能提示对端粒酶抑制剂的差异性敏感性

2025-09-010
PRE
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors

口服iptacopan单药治疗阵发性夜间血红蛋白尿症:来自在抗C5治疗患者中进行的开放标签、随机、III期APPLY-PNH试验和既往未经补体抑制剂治疗的患者的开放标签、单臂、III期APPOINT-PNH试验的最终48周结果

2025-05-280
PRE
Clonal hematopoiesis in large granular lymphocytic leukemia
LEUKEMIA
IF13.4
2024-11-210
PRE
Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

急性髓系白血病患者伴自身免疫性疾病史的基因分型与生存分析

BLOOD
IF23.1
2024-11-050
PRE